Logo
x

Search

Subscribe Now

Hepatocellular carcinoma

Roche Collaborates with Tempest to Evaluate TPST-1120 in a Combination Study as 1L Treatment for Hepatocellular Carcinoma

Roche Collaborates with Tempest to Evaluate TPST-1120 in a Combination Study as 1L Treatment for Hepatocellular Carcinoma

  • March 4, 2021
Innovent Report Results of Dual Regimen in P-III ORIENT-32 Study as 1L Therapy for Advanced HCC

Innovent Report Results of Dual Regimen in P-III ORIENT-32 Study as 1L Therapy for Advanced HCC

  • September 28, 2020
Roche's Tecentriq + Bevacizumab Receive Health Canada's Approval as 1L Treatment for Unresectable or Metastatic Hepatocellular Carcinoma

Roche's Tecentriq + Bevacizumab Receive Health Canada's Approval as 1L Treatment for Unresectable or Metastatic Hepatocellular Car...

  • August 19, 2020
Medivir's MIV-818 Receives EC's Orphan Medicinal Product Designation to Treat Hepatocellular Carcinoma

Medivir's MIV-818 Receives EC's Orphan Medicinal Product Designation to Treat Hepatocellular Carcinoma

  • July 3, 2020
Roche's Tecentriq + Avastin Receives the US FDA's Approval for Unresectable or Metastatic Hepatocellular Carcinoma

Roche's Tecentriq + Avastin Receives the US FDA's Approval for Unresectable or Metastatic Hepatocellular Carcinoma

  • June 2, 2020
BMS' Opdivo (nivolumab) + Yervoy (ipilimumab) Receive the US FDA's Approval for Patients with Hepatocellular Carcinoma Prior Treated with Sorafenib

BMS' Opdivo (nivolumab) + Yervoy (ipilimumab) Receive the US FDA's Approval for Patients with Hepatocellular Carcinoma Prior Treat...

  • March 11, 2020
Image

Incisive News in 3 Shots.

Contact Us

Our Information

Follow Us

Copyright © 2024 PharmaShots - All Rights Reserved.